Chardan and EF Hutton acted as joint book running managers for the offering.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SONN:
- Sonnet announces pricing of $15M underwritten public offering
- Sonnet completes two IND-enabling toxicology studies with SON-1210
- Sonnet BioTherapeutics files to sell common stock, warrants, no amount given
- Sonnet BioTherapeutics announces data in Phase 1 trial of SON-1010
- Sonnet BioTherapeutics, Roche collaborate for SON-1010 with atezolizumab